Screener
Viking Therapeutics VKTX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
FAQ
- What is Viking Therapeutics's EPS (basic)?
- Viking Therapeutics (VKTX) reported EPS (basic) of -$1.37 in Q1 2026.
- How has Viking Therapeutics's EPS (basic) changed year-over-year?
- Viking Therapeutics's EPS (basic) decreased by 234.1% year-over-year, from -$0.41 to -$1.37.
- What is the long-term trend for Viking Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Viking Therapeutics's EPS (basic) has grown at a 45.6% compound annual growth rate (CAGR), from -$0.71 to -$3.19.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Viking Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude